ArticlemSphere2020
ClbR Is the Key Transcriptional Activator of Colibactin Gene Expression in Escherichia coli.
Article in mSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 41 citations in OpenAlex.
- Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia.Nature communications · 2024Trial
- Presence and copy number variations ofIranian journal of microbiology · 2026Article
- Genomic Characterization ofMicroorganisms · 2025Article
- Genome-scale CRISPR/Cas9 screening reveals the role ofmSphere · 2025Article
- Less is more: the lack of autoinducer-2-dependent quorum sensing promotes competitive fitness ofFrontiers in cellular and infection microbiology · 2025Article
- Article
- Analysis of the partial sequencing of clbA, clbB and clbQ in Escherichia coli isolates that produce colibactin and multilocus sequence typing.Scientific reports · 2024Article
- Current understandings of colibactin regulation.Microbiology (Reading, England) · 2024Review
- The synthesis of the novelFrontiers in microbiology · 2024Review
- Bacteria in cancer initiation, promotion and progression.Nature reviews. Cancer · 2023Review
- D-Serine reduces the expression of the cytopathic genotoxin colibactin.Microbial cell (Graz, Austria) · 2023Article
- Escherichia coli BarA-UvrY regulates the pks island and kills Staphylococci via the genotoxin colibactin during interspecies competition.PLoS pathogens · 2022Article
- Pangenome analysis of Enterobacteria reveals richness of secondary metabolite gene clusters and their associated gene sets.Synthetic and systems biotechnology · 2022Article
- Article
- Evolution of Polymyxin Resistance Regulates Colibactin Production inACS chemical biology · 2021Article
- Leveraging Microbial Genomes and Genomic Context for Chemical Discovery.Accounts of chemical research · 2021Article
- Insights into evolution and coexistence of the colibactin- and yersiniabactin secondary metabolite determinants in enterobacterial populations.Microbial genomics · 2021Article
- Shining a Light on Colibactin Biology.Toxins · 2021Review
- Insights into the acquisition of theMicrobial genomics · 2021Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colibactin is a nonribosomal peptide/polyketide hybrid natural product expressed by different members of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.